All PlansCoverageLow impact
Intraocular Radiotherapy for Age-Related Macular Degeneration
Blue Cross & Blue Shield of Mississippi·Ophthalmology·Medical Policy
We identified it
Jun 20, 2026
Summary
This policy confirms that all forms of intraocular radiotherapy (brachytherapy, proton beam therapy, and stereotactic radiotherapy) for age-related macular degeneration remain investigational and not covered. No changes were made in the most recent review - this is a reaffirmation of existing coverage policy.
Action Required
No immediate action required. Continue to deny claims for intraocular radiotherapy procedures for age-related macular degeneration as investigational. Ensure billing team is aware these procedures remain non-covered.